# Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68
Ticker: MLYS
Company: Mineralys Therapeutics
Source: Mineralys Therapeutics
Published: 2026-06-08 20:05 EST
Original Source URL: https://ir.mineralystx.com/news-events/press-releases/detail/107/mineralys-therapeutics-to-participate-in-the-goldman-sachs
## Summary

RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on…...

## Article Body
RADNOR, Pa., June 08, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Goldman Sachs 47th Annual Global Healthcare Conference being held in Miami on June 8-10, 2026.

| Goldman Sachs 47th Annual Global Healthcare Conference |  |
| --- | --- |
| Date: | Tuesday, June 9, 2026 |
| Time: | 2:40pm ET |
| Format: | Fireside Chat |
| Webcast Link |  |

A live webcast of this fireside chat can also be accessed on the “ News & Events ” page in the Investors section of the Mineralys Therapeutics website.

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com . Follow Mineralys on LinkedIn , Twitter and Bluesky .

Contact:

Investor Relations investorrelations@mineralystx.com

Media Relations Melyssa Weible Elixir Health Public Relations Email: mweible@elixirhealthpr.com

Source: Mineralys Therapeutics, Inc. Released June 8, 2026
## Recent Company News
- 2026-06-14 14:00 EST — [Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-presents-late-breaking-data-on-lorundrostat-and-heart-fai-35eaa6f1) — Source: Mineralys Therapeutics
- 2026-06-08 20:05 EST — [Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-participate-in-the-goldman-sachs-47th-annual-global-he-6027ff68) — Source: Mineralys Therapeutics
- 2026-06-08 11:00 EST — [Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-to-present-late-breaking-data-on-lorundrostat-at-the-endo-03fb3c48) — Source: Mineralys Therapeutics
- 2026-06-03 10:05 EST — [Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Mineralys Therapeutics
- 2026-06-03 10:00 EST — [Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing](https://biopharmsignal.com/news/MLYS/mineralys-therapeutics-announces-repurchase-of-royalty-obligations-in-tanabe-license-agreement-and-concurrent-financing) — Source: Mineralys Therapeutics
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)